Patent · US Active

TGFβ antibodies, methods and uses

US12281159B2 · kind B2 · utility

0Cited by

14References

26Claims

0Family size

Assignee

Scholar Rock, Inc. · US

Inventors

Gregory J. Carven · Maynard, US
Thomas Schurpf · Cambridge, US
Katherine Turner · Melrose, US

Key dates

Filing date	May 25, 2021
Grant date	Apr 22, 2025
Priority date	—
Expiry date	Nov 1, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

ProTGFβ1-GARP complex-selective antibodies, polynucleotides capable of encoding the proTGFβ1-GARP complex-selective antibodies or antigen-binding fragments, cells expressing proTGFβ1-GARP complex-selective antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled proTGFβ1-GARP complex-selective antibodies or antigen-binding fragments may be used to enhance an immune response in a subject, for example, against a cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.